Cagrisema

Clinical evidence

Metabolic & weight loss

Novo's bet on 25% weight loss landed at 22.7% and lost the head-to-head — still the number-two drug in its class.

What it is

Cagrisema is a fixed-dose combination of semaglutide (the GLP-1 in Ozempic) and cagrilintide, a long-acting analog of the appetite hormone amylin — both at 2.4 mg in one weekly pen. It's investigational: an NDA was filed in late 2025, but it is not yet FDA-approved.

How it works

It hits two appetite pathways at once. Semaglutide slows digestion and quiets post-meal hunger through the hindbrain. Cagrilintide binds amylin and related receptors to reinforce the 'I'm full' signal. Two sensors, one weekly shot — and the second mechanism is genuinely additive, not a rebranded GLP-1.

What people report

✦Demonstrated ~22.7% average weight loss in phase-3 trials
✦60% of patients lost at least 20% of body weight
✦Second-highest weight-loss number ever recorded in a phase-3 obesity trial
✦A real option for people who tolerated semaglutide and want more

Typical use

Once weekly by injection, with a standard dose-titration ramp, as a chronic medication once approved.

Dosing reference

2.4 mg / 2.4 mg in a dual-chamber pen, weekly. Prescription only — no lawful US pharmacy access before approval exists.

Reference only — not a recommendation. Verify via primary sources.

Watch for

GI side effects ran higher than semaglutide alone, and the head-to-head against tirzepatide missed its target (23% vs 25.5%). Expect rebound on discontinuation, same as every drug in the class.

Notes

Gray-market vendor versions are research supply, not a workaround for an unapproved drug. FDA decision expected late 2026.

Understand the full reconstitution process →

Educational content — not medical advice.